← Eichor
Study identifier: NCT06533163 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Low-Intensity Oscillatory Magnetic Therapy in Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) - An Exposure-time Escalation Pilot Trial

Condition: Glioblastoma Multiforme  ·  Sponsor: BioTex, Inc.

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The clinical investigation is a non-randomized, multicenter, open-label, prospective, exposure-time escalation clinical investigation. The clinical investigation is designed to assess the clinical safety and performance of the Oncomagnetic Device.

This description comes directly from the study's public registry record.

Talk to the study team

Ashok Gowda  ·  713-741-0111  ·  ashok@biotexmedical.com

Madeline Meier  ·  713-741-0111  ·  madeline.meier@biotexmedical.com

Always discuss trial participation with your own doctor first.

Locations (6)

Clinical Center StuttgartStuttgart, Baden-Wurttemberg, GermanyRecruiting
Technical University of MunichMünchen, Bavaria, GermanyRecruiting
University Hospital BonnBonn, North Rhine-Westphalia, GermanyRecruiting
Clinical Center LünenLünen, North Rhine-Westphalia, GermanyRecruiting
University Hospital LeipzigLeipzig, Saxony, GermanyRecruiting
Medical Center MannheimMannheim, GermanyRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06533163